# Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients

> **NCT02376296** · — · COMPLETED · sponsor: **Saladax Biomedical, Inc.** · enrollment: 35 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** docetaxel
- **OTHER:** Blood draws

## Key facts

- **NCT ID:** NCT02376296
- **Lead sponsor:** Saladax Biomedical, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02
- **Primary completion:** 2018-02-10
- **Final completion:** 2018-02-10
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2022-02-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02376296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02376296, "Observational Study of Docetaxel Exposure in Metastatic Prostate Cancer Patients". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02376296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*